Express Scripts notes that these prescriptions may not, in fact, be for ADHD.
The Gray Lady surveys the landscape of attention deficit disorder marketing.
Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.
The uptick is being linked to looser DSM guidelines.
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
Healthcare critics continue to spend on anti-ACA ads; Janssen plunges into the microbiome; Lilly gets adult ADHD indication in UK; Sanofi pulls two drugs; and Aveo lays off 140.
Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
Taking a page from Sanofi, Shire is preparing to launch a developer challenge "to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood."
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.